AU2021228286A1 - Pyridazine derivatives for modulating nucleic acid splicing - Google Patents

Pyridazine derivatives for modulating nucleic acid splicing Download PDF

Info

Publication number
AU2021228286A1
AU2021228286A1 AU2021228286A AU2021228286A AU2021228286A1 AU 2021228286 A1 AU2021228286 A1 AU 2021228286A1 AU 2021228286 A AU2021228286 A AU 2021228286A AU 2021228286 A AU2021228286 A AU 2021228286A AU 2021228286 A1 AU2021228286 A1 AU 2021228286A1
Authority
AU
Australia
Prior art keywords
compound
alkyl
heterocyclyl
heteroaryl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021228286A
Other languages
English (en)
Inventor
Anant A. AGRAWAL
Allen T. Hopper
Dominic Reynolds
Michael Walker SEILER
Peter Smith
Frederic VAILLANCOURT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Remix Therapeutics Inc
Original Assignee
Remix Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remix Therapeutics Inc filed Critical Remix Therapeutics Inc
Publication of AU2021228286A1 publication Critical patent/AU2021228286A1/en
Priority to AU2024201568A priority Critical patent/AU2024201568A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Replacement Of Web Rolls (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2021228286A 2020-02-28 2021-02-28 Pyridazine derivatives for modulating nucleic acid splicing Abandoned AU2021228286A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024201568A AU2024201568A1 (en) 2020-02-28 2024-03-08 Pyridazine derivatives for modulating nucleic acid splicing

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202062983537P 2020-02-28 2020-02-28
US62/983,537 2020-02-28
US202063007134P 2020-04-08 2020-04-08
US63/007,134 2020-04-08
US202063040474P 2020-06-17 2020-06-17
US63/040,474 2020-06-17
US202063072781P 2020-08-31 2020-08-31
US63/072,781 2020-08-31
US202063126491P 2020-12-16 2020-12-16
US63/126,491 2020-12-16
PCT/US2021/020160 WO2021174170A1 (en) 2020-02-28 2021-02-28 Pyridazine dervatives for modulating nucleic acid splicing

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024201568A Division AU2024201568A1 (en) 2020-02-28 2024-03-08 Pyridazine derivatives for modulating nucleic acid splicing

Publications (1)

Publication Number Publication Date
AU2021228286A1 true AU2021228286A1 (en) 2022-10-06

Family

ID=75278334

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2021228286A Abandoned AU2021228286A1 (en) 2020-02-28 2021-02-28 Pyridazine derivatives for modulating nucleic acid splicing
AU2021228288A Pending AU2021228288A1 (en) 2020-02-28 2021-02-28 Pyridazine derivatives for modulating nucleic acid splicing
AU2024201568A Pending AU2024201568A1 (en) 2020-02-28 2024-03-08 Pyridazine derivatives for modulating nucleic acid splicing

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2021228288A Pending AU2021228288A1 (en) 2020-02-28 2021-02-28 Pyridazine derivatives for modulating nucleic acid splicing
AU2024201568A Pending AU2024201568A1 (en) 2020-02-28 2024-03-08 Pyridazine derivatives for modulating nucleic acid splicing

Country Status (11)

Country Link
US (2) US20230365526A1 (https=)
EP (2) EP4110774A1 (https=)
JP (2) JP2023515617A (https=)
KR (2) KR20220157407A (https=)
CN (2) CN115551847A (https=)
AU (3) AU2021228286A1 (https=)
BR (2) BR112022017089A2 (https=)
CA (2) CA3169667A1 (https=)
IL (2) IL295953A (https=)
MX (2) MX2022010634A (https=)
WO (2) WO2021174176A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019028440A1 (en) 2017-08-04 2019-02-07 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING SPLICING
WO2020163248A1 (en) 2019-02-04 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
CN114126613A (zh) 2019-02-05 2022-03-01 斯基霍克疗法公司 用于调节剪接的方法和组合物
EP3920915A4 (en) * 2019-02-05 2022-10-05 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING SPLICE
CN113661162A (zh) 2019-02-06 2021-11-16 斯基霍克疗法公司 用于调节剪接的方法和组合物
WO2020163544A1 (en) 2019-02-06 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
BR112022023025A2 (pt) 2020-05-13 2023-03-28 Chdi Foundation Inc Moduladores de htt para tratar doença de huntington
US20240368163A1 (en) 2021-08-30 2024-11-07 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2023034836A1 (en) * 2021-08-30 2023-03-09 Remix Therapeutics Inc. Compounds and methods for modulating splicing
US20250127789A1 (en) * 2021-11-04 2025-04-24 Skyhawk Therapeutics, Inc. Compositions useful for modulating splicing
US12281116B2 (en) 2021-11-17 2025-04-22 Chdi Foundation, Inc. HTT modulators for treating Huntington's disease
US20250101006A1 (en) * 2022-01-31 2025-03-27 Novartis Ag Process for the synthesis of pyrazolyl derivatives useful as anti-cancer agents
CA3242153A1 (en) * 2022-04-01 2023-10-05 Tyk Medicines, Inc. COMPOUND SERVING AS A KINASE INHIBITOR AND ITS USE
EP4577543A1 (en) * 2022-08-22 2025-07-02 Redx Pharma Limited Pyrido-pyrazoles as inhibitors of ddr's for the treatment of fibrotic disorders and cancer
WO2024182747A2 (en) * 2023-03-01 2024-09-06 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2025211457A1 (ja) * 2024-04-05 2025-10-09 日本新薬株式会社 Ｃｕｇリピートｒｎａとｍｂｎｌタンパクとの結合阻害化合物および医薬

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7160876B2 (en) * 2003-12-22 2007-01-09 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
DK2812004T3 (en) 2012-02-10 2018-10-15 Ptc Therapeutics Inc COMPOUNDS FOR TREATMENT OF SPINAL MUSCLE DROPHY
US8729263B2 (en) 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
US9521848B2 (en) * 2013-07-31 2016-12-20 Sumitomo Chemical Company, Limited Tetrazolinone compound and use therefor
MX381224B (es) * 2014-10-31 2025-03-12 Massachusetts Gen Hospital Potentes moduladores de gamma-secretasa.
WO2016128343A1 (en) 2015-02-09 2016-08-18 F. Hoffmann-La Roche Ag Compounds for the treatment of cancer
EP4249472A3 (en) 2015-05-30 2023-12-13 PTC Therapeutics, Inc. Methods for modulating rna splicing
IL294124B2 (en) * 2015-12-10 2024-02-01 Ptc Therapeutics Inc Methods for treating huntington's disease
EA201991309A1 (ru) 2016-11-28 2019-11-29 Способы модуляции сплайсинга рнк
WO2018140578A1 (en) * 2017-01-25 2018-08-02 President And Fellows Of Harvard College Non-fullerene solar panel acceptor compounds
KR20200017476A (ko) * 2017-06-14 2020-02-18 피티씨 테라퓨틱스, 인크. Rna 스플라이싱의 변경 방법
WO2019028440A1 (en) * 2017-08-04 2019-02-07 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING SPLICING
KR20200057071A (ko) 2017-09-25 2020-05-25 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱 조절제의 스크리닝 및 확인을 위한 방법 및 조성물
IL273924B2 (en) * 2017-10-20 2024-07-01 Univ Vanderbilt Antagonists of the muscarinic acetylcholine receptor m4
IL276411B2 (en) * 2018-02-02 2024-04-01 Univ Vanderbilt M4 muscarinic acetylcholine receptor antagonists
CN112272666A (zh) 2018-04-10 2021-01-26 斯基霍克疗法公司 用于治疗癌症的化合物
TWI823932B (zh) * 2018-05-11 2023-12-01 中國大陸商迪哲（江蘇）醫藥有限公司 三唑并嘧啶化合物及其在治療癌症中之用途

Also Published As

Publication number Publication date
EP4110774A1 (en) 2023-01-04
CN115551847A (zh) 2022-12-30
JP2023515618A (ja) 2023-04-13
MX2022010637A (es) 2023-01-19
WO2021174176A9 (en) 2022-09-15
IL295954A (en) 2022-10-01
EP4110771A1 (en) 2023-01-04
CA3169667A1 (en) 2021-09-02
CN115551843A (zh) 2022-12-30
US20230365526A1 (en) 2023-11-16
WO2021174176A1 (en) 2021-09-02
BR112022017107A2 (pt) 2022-11-16
CA3169643A1 (en) 2021-09-02
US20230140983A1 (en) 2023-05-11
MX2022010634A (es) 2023-01-19
IL295953A (en) 2022-10-01
WO2021174170A1 (en) 2021-09-02
KR20220157407A (ko) 2022-11-29
BR112022017089A2 (pt) 2022-11-16
KR20220158236A (ko) 2022-11-30
JP2023515617A (ja) 2023-04-13
WO2021174170A9 (en) 2022-09-15
AU2021228288A1 (en) 2022-09-22
AU2024201568A1 (en) 2024-03-28

Similar Documents

Publication Publication Date Title
AU2021228286A1 (en) Pyridazine derivatives for modulating nucleic acid splicing
WO2021174163A1 (en) Fused bicyclic compounds useful for modulating nucleic acid splicing
IL297137A (en) Splicing Modulation Compounds and Methods
AU2021253571A1 (en) Compounds and methods for modulating splicing
AU2021228285A1 (en) Compounds and methods for modulating splicing
AU2021228770A1 (en) Thiophenyl derivatives useful for modulating nucleic acid splicing
IL299543A (en) 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases
EP4395889A1 (en) Compounds and methods for modulating splicing

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted